CYTOKINETICS INC

For the period ended Dec 31, 2024. Filed Feb 27, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 27, 2025

CYTK$56.18+1.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except per share data)

	Years Ended December 31,
	2024	2023	2022
Revenues:
License and milestone revenues	$15,000	$3,500	$1,000
Collaboration revenues	3,474	4,030	6,588
Realization of revenue participation right purchase agreement	—	—	87,000
Total revenues	18,474	7,530	94,588
Operating expenses:
Research and development	339,408	330,123	240,813
General and administrative	215,314	173,612	177,977
Total operating expenses	554,722	503,735	418,790
Operating loss	(536,248)	(496,205)	(324,202)
Interest expense	(37,701)	(28,306)	(19,414)
Loss on extinguishment of debt	—	—	(24,939)
Non-cash interest expense on liabilities related to revenue participation right purchase agreements	(48,811)	(29,362)	(31,742)
Interest and other income, net	51,534	27,629	11,342
Change in fair value of derivative liabilities	1,300	—	—
Change in fair value of liabilities related to RPI Transactions	(19,600)	—	—
Net loss	$(589,526)	$(526,244)	$(388,955)
Net loss per share — basic and diluted	$(5.26)	$(5.45)	$(4.33)
Weighted-average number of shares used in computing net loss per share — basic and diluted	111,979	96,524	89,825
Other comprehensive gain (loss):
Unrealized gain (loss) on available-for-sale securities, net	2,153	3,600	(2,721)
Foreign currency translation adjustments	255	(20)	—
Comprehensive loss	$(587,118)	$(522,664)	$(391,676)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.